Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $1,272,588.00 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 51,900 shares of Kestra Medical Technologies stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $24.52, for a total value of $1,272,588.00. Following the sale, the insider directly owned 475,215 shares in the company, valued at approximately $11,652,271.80. This trade represents a 9.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Brian Daniel Webster also recently made the following trade(s):

• On Monday, August 3rd, Brian Daniel Webster sold 13,017 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.92, for a total value of $311,366.64.
• On Friday, July 31st, Brian Daniel Webster sold 8,948 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.60, for a total value of $202,224.80.
• On Thursday, July 30th, Brian Daniel Webster sold 7,857 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.72, for a total value of $178,511.04.
• On Monday, June 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.81, for a total value of $312,150.00.
• On Friday, May 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.96, for a total value of $314,400.00.

Kestra Medical Technologies Price Performance

Shares of KMTS opened at $26.40 on Friday. Kestra Medical Technologies, Ltd. has a one year low of $14.30 and a one year high of $30.00. The stock’s fifty day moving average is $22.96 and its 200-day moving average is $22.57. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -10.91 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. Equities analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD raised its holdings in shares of Kestra Medical Technologies by 137.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after purchasing an additional 2,529,851 shares in the last quarter. Brown Advisory Inc. boosted its holdings in Kestra Medical Technologies by 34.1% during the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock worth $44,775,000 after buying an additional 428,996 shares in the last quarter. Alliancebernstein L.P. grew its position in Kestra Medical Technologies by 13.7% in the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock worth $35,449,000 after buying an additional 179,885 shares during the last quarter. Eventide Asset Management LLC increased its holdings in shares of Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after buying an additional 65,288 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of Kestra Medical Technologies by 180.8% during the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after acquiring an additional 612,343 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on KMTS shares. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Oppenheimer assumed coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They issued a “market perform” rating for the company. BTIG Research increased their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Wall Street Zen upgraded Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $27.83.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.